Accelerating the discovery of new treatments for immune-inflammatory diseases, including lupus and systemic sclerosis, is the focus of a new strategic research collaboration between Servier and UCL.
“Collaboration with academia is one of the main levers of our strategy to contribute to research to accelerate the discovery and development of innovative treatments for patients”, said Claude Bertrand, Executive Vice-President Research & Development at Servier. The UCL team we are working with have considerable expertise in both lupus and systemic sclerosis, and they are based at one of the top institutions for medical and health research globally.”
Each year, the UCL welcomes more than 41,500 students from 150 countries. It regularly ranks among the top 10 universities in the world, particularly in terms of research.
Announcing a new strategic research collaboration between @Servier and @UCL. This partnership will focus on accelerating the discovery of new treatments for immune-inflammatory diseases, including scleroderma and lupus.
Read the news story 👉 https://t.co/rhEmEmIHmv pic.twitter.com/RBOEbjkyVU
— UCL Innovation & Enterprise (@UCLEnterprise) December 12, 2019